Evidence map›Paper›PMID 33717367›Full record

ReviewThe open respiratory medicine journal2020

Novel and Controversial Therapies in COVID-19.

Romil Singh, Likhita Shaik, Ishita Mehra, Rahul Kashyap, Salim Surani

Open access · diamondAbstract readReview
In one paragraph

Review in The open respiratory medicine journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. The Role of Micronutrients to Support Immunity for COVID-19 Prevention.Revista brasileira de farmacognosia : orgao oficial da Sociedade Brasileira de Farmacognosia · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Romil SinghDepartment of Medicine, Metropolitan Hospital, Jaipur, Rajasthan, India.
Likhita ShaikDepartment of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Ishita MehraDepartment of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Rahul KashyapDepartment of Anesthesiology and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Salim SuraniDepartment of Pulmonary & Critical Care Medicine & Pharmacology, Texas A&M University, TX, USA.
Mayo Clinic in Arizona · USJaipur Golden Hospital · INTexas A&M University · USUniversity of South Alabama Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease (COVID-19) pandemic, which has led scientists all over the world to push for the identification of novel therapies for COVID-19. The lack of a vaccine and specific treatment has led to a surge of novel therapies and their publicity in recent times. Under these unprecedented circumstances, a myriad of drugs used for other diseases is being evaluated and repositioned to treat COVID-19 (example- Remdesivir, Baricitinib). While multiple trials for potential drugs and vaccines are ongoing, and there are many unproven remedies with little or no supporting evidence. Presently, discussions are revolving around the use of multivitamins (Vitamin, C, D, A), minerals (selenium, zinc), probiotics, flavonoids, polyphenols, and herbal remedies (curcumin, artemisinin, herbal drinks). Our review delves further into the details of some of these controversial therapies for COVID-19.

Indexed as

AntioxidantControversial therapyCOVID-19Novel therapyPneumoniaReview

Identifiers

PMID33717367
PMCPMC7931150
OpenAlexW3103113200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.